Elucidating mechanism cellular uptake removal
We concluded that MRC NPs uptake in breast cancer cells is more effective than in normal cells with regard to both the amount of internalized nanomaterial and the achievement of more strategic intracellular distribution.
Overall, our study demonstrates that cellular response after exposure to MRC NPs varies among cell lines and that different basal expression levels of clathrin in cells can define the biological pathway of MRC NPs and their uptake efficacy.
The association of maghemite–rhodium citrate (MRC) nanoparticles (NPs) has the potential to increase specificity of the cytotoxic action.
However, the interaction of these NPs with cells, their uptake mechanism, and subcellular localization need to be elucidated.
Primary cultures of HNTMCs from dental pulp were obtained from health volunteers, who provided informed consent, and with approval from the human ethics committee of the University of Brasilia (104934/2008).
S141582 Checked for plagiarism Yes Review by Single-blind Peer reviewers approved by Dr Thiruganesh Ramasamy Peer reviewer comments 3 Editor who approved publication: Prof. Thomas J Webster Institute of Chemistry, Federal University of Goiás, Goiânia, Brazil Abstract: Nanocarriers have the potential to improve the therapeutic index of currently available drugs by improving their efficacy and achieving therapeutic steady-state levels over an extended period.
However, MRC interaction with cells, their uptake mechanism, and subcellular localization are not understood.
Despite remarkable advances in nanoscience, relatively little is known about the intracellular destination and mechanism of action of NPs.
The size and shape of the particles are important parameters with regard to the space available in these endocytic compartments.
In the present study, the uptake and distribution of the most stable NPs composition based on maghemite were analyzed in vitro in different cell lines.
This work evaluates the uptake mechanism of MRC NPs in metastatic and nonmetastatic breast cancer-cell models, comparing them to a nontumor cell line.